[Aspects of pneumocystosis seen in a French pneumonology department in 1987-1988]

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

[Aspects of pneumocystosis seen in a French pneumonology department in 1987-1988]

Rev Med Interne. 1990 May-Jun;11(3):197-200. Unique Identifier : AIDSLINE MED/91262251
Dautzenberg B; Antoun F; Benichou S; Postal MJ; Broussier PM; Sors C; Service de pneumologie, G.H. Pitie-Salpetriere, Paris.

Abstract: Over a 2 years' period, 49 AIDS patients and 3 non AIDS patients were treated for pneumocystosis in our chest department. Forty-six were male and 6 were female. Pneumocystosis was the first opportunistic infection in 77 p 100 of patients. Fever above 38.5 degrees C was the major symptom in 92 p 100. Cough was present in 90 p 100 and dyspnoea in 94 p 100. Clinical symptoms had begun 21.7 +/- 15.7 days before diagnosis. Mean PaO2 value was 50.9 +/- 15.7 mmHg. Forty-eight patients were initially treated by daily intravenous administration of trimethoprim 960 mg and sulfamethoxazole 4,800 mg. Three patients received a pentamidine aerosol and one received DFMO. Treatment was effective in 39 patients; 11 patients died between the 5th and the 29th days of treatment; 2 had an early relapse. Fever disappeared after 9.8 +/- 6.6 days, and blood gases returned to normal within 10.8 +/- 7.7 days. All patients whose PaO2 was above 56 mmHg were cured. Thus, the trimethoprim-sulfamethoxazole combination proved active in the treatment of pneumocystosis. Other treatments are useful in case of side-effects or failure of the initial therapy. Failures can be suspected on the fourth day of treatment and in such cases CMV co-infection must be looked for and treated.

Keywords: Acquired Immunodeficiency Syndrome/*COMPLICATIONS Adult Aged English Abstract Female France/EPIDEMIOLOGY Human Male Middle Age Opportunistic Infections/DRUG THERAPY/EPIDEMIOLOGY/ETIOLOGY Pneumonia, Pneumocystis carinii/DRUG THERAPY/EPIDEMIOLOGY/ *ETIOLOGY Prognosis Retrospective Studies JOURNAL ARTICLE
910930
M9190664

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .